Publicação
Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use
| dc.contributor.author | Aguiara, Sandra I. | |
| dc.contributor.author | Brito, Maria J. | |
| dc.contributor.author | Gonçalo-Marques, José | |
| dc.contributor.author | Cristino, José Melo | |
| dc.contributor.author | Ramirez, Mário | |
| dc.date.accessioned | 2012-02-22T12:30:59Z | |
| dc.date.available | 2012-02-22T12:30:59Z | |
| dc.date.issued | 2010-07-19 | |
| dc.description | © 2010 Elsevier Ltd. All rights reserved. | por |
| dc.description.abstract | We characterized 353 isolates responsible for pediatric invasive pneumococcal infections (IPD) in Portugal between 2006 and 2008. Serotypes included in the seven-valent conjugate vaccine (PCV7) accounted for 17% of IPD. Serotypes 1, 7F and 19A were the most frequent causes of IPD and the later consolidated as the most frequent serotype among erythromycin and penicillin non-susceptible isolates. Serotype 1 was associated with older children and empyemas, while serotype 19A was associated with IPD in younger (<2 years) children. The higher valency vaccines PCV10 and PCV13 have a potentially superior coverage, 55% and 83% respectively, but non-vaccine serotypes are emerging as important causes of IPD. A decline of resistance with patient age was noted. Comparing with previous data from Portugal, this study showed a continued decline of PCV7 serotypes and that overall resistance has stabilized following the initial decline of the first post-PCV7 years. | eng |
| dc.description.sponsorship | S.I. Aguiar was supported by grant SFRH/BD/27518/2006 from Fundac¸ ão para a Ciência e Tecnologia, Portugal. This work was partially supported by Fundac¸ ão para a Ciência e Tecnologia, Portugal (PTDC/SAU-ESA/64888/2006 and PIC/IC/83065/2007), Fundac¸ ão Calouste Gulbenkian and the European Union (CAREPNEUMO – Combating antibiotic resistance pneumococci by novel strategies based on in vivo and in vitro host–pathogen interactions, FP7-HEALTH-2007-223111) and unrestricted research grants from Pfizer and Glaxo SmithKline. | por |
| dc.identifier.citation | Vaccine 28 (2010) 5167–5173 | por |
| dc.identifier.issn | 0264-410X | |
| dc.identifier.uri | http://hdl.handle.net/10451/5360 | |
| dc.identifier.uri | http://dx.doi.org/10.1016/j.vaccine.2010.06.008 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Elsevier | por |
| dc.subject | Streptococcus pneumoniae | por |
| dc.subject | Conjugate vaccines | por |
| dc.subject | Antimicrobial resistance | por |
| dc.subject | Pediatrics | por |
| dc.title | Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 5173 | por |
| oaire.citation.issue | Volume 28, Issue 32 | por |
| oaire.citation.startPage | 5167 | por |
| oaire.citation.title | Vaccine | por |
| person.familyName | Melo Cristino | |
| person.givenName | José | |
| person.identifier.ciencia-id | 871E-6AD6-F37C | |
| person.identifier.orcid | 0000-0001-8643-1722 | |
| person.identifier.rid | H-3726-2013 | |
| person.identifier.scopus-author-id | 7004053640 | |
| rcaap.rights | restrictedAccess | por |
| rcaap.type | article | por |
| relation.isAuthorOfPublication | acefbfd7-46d0-4429-80b1-ad159fe4ca95 | |
| relation.isAuthorOfPublication.latestForDiscovery | acefbfd7-46d0-4429-80b1-ad159fe4ca95 |
Ficheiros
Principais
1 - 1 de 1
Miniatura indisponível
- Nome:
- Article.pdf
- Tamanho:
- 174.59 KB
- Formato:
- Adobe Portable Document Format
- Descrição:
- Artigo